1. Home
  2. CYTK vs MTH Comparison

CYTK vs MTH Comparison

Compare CYTK & MTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CYTK
  • MTH
  • Stock Information
  • Founded
  • CYTK 1997
  • MTH 1985
  • Country
  • CYTK United States
  • MTH United States
  • Employees
  • CYTK N/A
  • MTH N/A
  • Industry
  • CYTK Biotechnology: Pharmaceutical Preparations
  • MTH Homebuilding
  • Sector
  • CYTK Health Care
  • MTH Consumer Discretionary
  • Exchange
  • CYTK Nasdaq
  • MTH Nasdaq
  • Market Cap
  • CYTK 4.4B
  • MTH 5.1B
  • IPO Year
  • CYTK 2004
  • MTH 1988
  • Fundamental
  • Price
  • CYTK $38.62
  • MTH $77.09
  • Analyst Decision
  • CYTK Buy
  • MTH Buy
  • Analyst Count
  • CYTK 13
  • MTH 10
  • Target Price
  • CYTK $71.58
  • MTH $83.61
  • AVG Volume (30 Days)
  • CYTK 1.4M
  • MTH 1.2M
  • Earning Date
  • CYTK 08-07-2025
  • MTH 07-23-2025
  • Dividend Yield
  • CYTK N/A
  • MTH 2.23%
  • EPS Growth
  • CYTK N/A
  • MTH N/A
  • EPS
  • CYTK N/A
  • MTH 8.78
  • Revenue
  • CYTK $85,738,000.00
  • MTH $6,216,250,000.00
  • Revenue This Year
  • CYTK $27.08
  • MTH N/A
  • Revenue Next Year
  • CYTK $652.09
  • MTH $6.75
  • P/E Ratio
  • CYTK N/A
  • MTH $8.77
  • Revenue Growth
  • CYTK 2635.74
  • MTH N/A
  • 52 Week Low
  • CYTK $29.31
  • MTH $59.27
  • 52 Week High
  • CYTK $59.39
  • MTH $106.99
  • Technical
  • Relative Strength Index (RSI)
  • CYTK 60.89
  • MTH 63.30
  • Support Level
  • CYTK $32.89
  • MTH $70.51
  • Resistance Level
  • CYTK $36.79
  • MTH $79.23
  • Average True Range (ATR)
  • CYTK 1.73
  • MTH 2.35
  • MACD
  • CYTK 0.15
  • MTH 0.60
  • Stochastic Oscillator
  • CYTK 91.77
  • MTH 84.90

About CYTK Cytokinetics Incorporated

Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

About MTH Meritage Homes Corporation

Meritage Homes Corp is engaged as a designer and builder of single-family attached and detached homes. It has operations in three regions: West, Central, and East, comprising ten states: Arizona, California, Colorado, Texas, Florida, Georgia, North Carolina, South Carolina, Tennessee, and Utah. The company operates with two principal business segments: homebuilding and financial services. The homebuilding segments are engaged in the business of acquiring and developing land, constructing homes, marketing and selling those homes, and providing warranty and customer services, and the financial services segment offers title and escrow, mortgage, and insurance services. The company generates key revenue from the homebuilding segment.

Share on Social Networks: